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ABSTRACT  36 
Mammalian poxviruses, including vaccinia virus (VACV), have evolved multiple 37 
mechanisms to evade the host type I interferon (IFN) responses at different 38 
levels, with viral proteins targeting IFN induction, signaling and antiviral effector 39 
functions. Avian poxviruses (avipoxviruses), which have been developed as 40 
recombinant vaccine vectors for permissive (i.e. poultry) and non-permissive (i.e. 41 
mammals, including humans) species, encode no obvious equivalents of any of 42 
these proteins. We show that fowlpox virus (FWPV) fails to induce chicken IFN-β 43 
(ChIFN2) and is able to block its induction by transfected poly(I:C), an analog of 44 
cytoplasmic double-strand (ds) RNA. A broad-scale loss-of-function genetic 45 
screen was used to find FWPV-encoded modulators of poly(I:C)-mediated 46 
ChIFN2 induction. It identified fpv012, a member of a family of poxvirus genes, 47 
highly expanded in the avipoxviruses (31 in FWPV; 51 in canarypox virus 48 
(CNPV), representing 15% of the total gene complement), encoding proteins 49 
containing N-terminal ankyrin repeats (ANKs) and C-terminal F-box-like motifs. 50 
Under ectopic expression, the first ANK of fpv012 is dispensable for inhibitory 51 
activity and the CNPV ortholog is also able to inhibit induction of ChIFN2. FWPV 52 
defective in fpv012 replicate well in culture and barely induce ChIFN2 during 53 
infection, suggesting other factors are involved in blocking IFN induction and 54 
resisting the antiviral effectors. Nevertheless, unlike parental and revertant 55 
viruses, the mutants induce moderate levels of expression of interferon 56 
stimulated genes (ISG), suggesting either that there is sufficient ChIFN2 57 
expression to partially induce the ISGs or the involvement of alternative, IFN-58 
independent pathways, that are also normally blocked by fpv012. 59 
60 
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INTRODUCTION 61 
The host antiviral type I interferon (IFN) system is targeted by many viruses (1), 62 
and poxviruses are no exception. The prototypic, mammalian poxvirus, vaccinia 63 
virus (VACV), encodes a number of proteins that have been shown to modulate 64 
the IFN system in diverse ways, as reviewed recently (2). Functionally they can 65 
be grouped into those that inhibit induction of IFN-β, such as NF-κB activation 66 
suppressor K1 (3) and TBK-1 adaptor binding protein, C6 (4); those that inhibit 67 
IFN signaling via the Jak/Stat pathway necessary to induce expression of IFN-68 
stimulated genes (ISG), such as soluble IFN receptor mimic B18 (5, 6) and Stat 69 
phosphorylation inhibitor H1 (7); and those that antagonize the activity of the 70 
major antiviral ISGs, such as double-stranded (ds) RNA-binding protein E3 (8) 71 
and eIF-2α mimic K3 (9).  72 
 73 
With the exception of H1, no orthologs (nor even any functional equivalents) of 74 
these modulators have been described in avian poxviruses. A diverse group of 75 
viruses isolated from more than 230 species of birds (10), and infecting only 76 
avian species, all avian poxviruses are grouped into the single Avipoxvirus genus 77 
of the Chordopoxvirinae sub-family (11), with Fowlpox virus (FWPV) as the type 78 
species. Like VACV, FWPV has been developed for use as a live recombinant 79 
vaccine vector, in both permissive (i.e. poultry) and non-permissive hosts (i.e. 80 
mammals, including humans, in which its replication is abortive) (12-18). 81 
Notably, a commercial FWPV recombinant vaccine (TROVACTM-H5) expressing 82 
the HA gene of H5N8 isolate A/turkey/Ireland/1378/83 has become the most 83 
extensively used live recombinant virus used in any sector, with some 2 billion 84 
doses used to counter highly pathogenic influenza H5N2 in Mexico up to 2005 85 
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(19). Another avipoxvirus, canarypox virus (CNPV), which is well diverged from 86 
FWPV (20), has been developed extensively for use in non-permissive 87 
mammalian hosts (21-23), with several licensed commercial vaccines available 88 
for diseases of livestock and companion animals. CNPV, as ALVACTM, was also the 89 
recombinant virus in the recent Thai HIV vaccine trial (RV144) that showed 90 
marginal indications of potential efficacy (24).  91 
 92 
We show that, in chicken cell culture, FWPV fails to induce chicken IFN-2 93 
(ChIFN2), believed to be the chicken equivalent of IFN-β (25, 26), and is able to 94 
block its induction by transfected poly(I:C), an analog of cytoplasmic double-95 
strand (ds) RNA. We have used a broad-scale genetic ‘loss-of-function’ screen, 96 
involving a library of 48 FWPV in vitro-generated mutants, each defective in a 97 
single, non-essential gene, to identify a gene involved in blocking induction of the 98 
ChIFN2 promoter mediated by the dsRNA mimic, poly(I:C). The screen identified 99 
a member of a poxvirus gene family that is far more extensive in avipoxviruses 100 
than in mammalian poxviruses and has not been previously associated with IFN-101 
modulation.  102 
 103 
MATERIALS AND METHODS 104 
 105 
Cells and viruses 106 
Primary chicken embryo fibroblast cells (CEF), produced from specific pathogen 107 
free (SPF)-quality embryos (10-day old) at the Institute for Animal Health 108 
(Compton, Berkshire, U.K.) were grown in 199 medium supplemented with 10% 109 
tryptone phosphate broth (TPB), 10% newborn bovine serum, nystatin and 110 
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penicillin/streptomycin.  DF-1 cells (27) obtained from the American Tissue 111 
Culture Collection (ATCC), were maintained in DMEM supplemented with 10% 112 
Foetal Bovine Serum (Autogen Bioclear) and penicillin/streptomycin. 113 
 114 
Attenuated FWPV strain FP9, used throughout this study, as well as its 115 
pathogenic European progenitor, HP1, have been described previously (28). 116 
Infectious bursal disease virus strain PBG98, a ‘mild’ vaccine strain from 117 
laboratory stocks, was propagated in CEF (29). 118 
 119 
Plasmids  120 
The ChIFN2 promoter reporter (pChIFN2lucter (30)) and the constitutive β-121 
galactosidase reporter plasmid (pJATlacZ (31)) have been previously described. 122 
Expression plasmids were constructed by cloning FWPV or CNPV genes into 123 
pEFPlink2 or pEFPlink2Flag (32). Sequences were amplified by PCR using 124 
oligonucleotides (Table 1) containing BamHI and SpeI (NcoI in the case of 125 
fpv213) sites and cloned into pEFPlink2 or pEFPlink2Flag restricted with BamHI 126 
and SpeI (NcoI in the case of fpv213). Plasmids were sequenced to ensure no 127 
errors had been introduced and reading frame was intact. 128 
 129 
Transfection of cells with poly(I:C) and assay of luciferase reporters 130 
Chicken DF-1 cells in 12-well plates were transfected with the ChIFN2 promoter 131 
reporter pChIFN2lucter (167ng) and the constitutive reporter plasmid pJATlacZ 132 
(167ng), sometimes additionally with an expression plasmid driving the 133 
overexpression of viral proteins or the control empty vector pEFPlink2 (250ng). 134 
Following recovery for 24 hours, cells were either left uninfected or infected 135 
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with infectious bursal disease virus (IBDV) attenuated vaccine PBG98, 136 
pathogenic FWPV HP1, parental or mutant attenuated FWPV FP9 (MOI 10). 137 
Following infection for 4 hours, cells, when appropriate, were transfected with 138 
poly(I:C) (10µg/ml) using Polyfect (Qiagen), as described by Childs et al. (30), 139 
and incubated for 16 hours. Luciferase assays were carried out and data were 140 
normalized using β-galactosidase measurements. 141 
 142 
β-galactosidase assay 143 
Cell lysate β-galactosidase concentrations were measured by incubation of 10µl 144 
of cell lysate with ortho-nitrophenyl-β-galactoside (50µl of 0.5 mg ml-1 diluted in 145 
60mM Na2HPO4.7H2O, 40mM Na2H2PO4.H2O, 10mM KCl, 1mM MgSO4.7H2O, 146 
2.7ml l-1 β-mercaptoethanol). The reaction was incubated at 37ºC until a yellow 147 
coloration had appeared when A420 was measured using a spectrophotometer.  148 
 149 
Analysis of gene expression by ribonuclease protection assay 150 
Total RNA was prepared from 9cm diameter dishes of confluent cells, treated as 151 
described above, using the acid phenol method and analyzed by ribonuclease 152 
(RNase) protection using the method of Zinn et al. (33) as described previously 153 
(34). To generate a probe against chicken β-actin (Ch-Act-β), a 158 bp fragment 154 
of CEF genomic DNA was amplified by PCR using the primers 5’-155 
CCCCATGGATGATATTGCTGCGC-3’ and 5’-156 
TAATACGACTCACTATAGCTGATGTCTGGGGCGACCCACGA-3’; the underlined 157 
region contains the T7 promoter allowing generation of RNA probe from the PCR 158 
product by transcription with T7 RNA polymerase. To generate a probe for 159 
ChIFN2, a PCR product (amplified using the primers 5’-160 
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CCCAGATCTCCTCCAGTACAGCCACCACATGGT-3’ and 5’-161 
CCCTCTAGACAGTCACTGGGTGTTGAGAC-3’) was cloned into pCRIIBlunt.Topo 162 
(Invitrogen). Orientation of the PCR product  within pCRII.Blunt.Topo was 163 
deduced by restriction mapping, it was linearized with the restriction enzyme 164 
EarI and transcribed using T7 polymerase to generate a 357bp RNA probe 165 
complementary to cellular mRNA. 166 
 167 
Construction of insertion knock-out mutant FWPV. 168 
Generation of a FWPV knockout library by insertion of the Escherichia coli 169 
xanthine-guanine phosphoribosyl-transferase (gpt) gene was carried out by PCR 170 
overlap extension (PCR-OE). To construct the knock-out FWPV, PCR-OE (using 171 
high fidelity Taq polymerase) was used to assemble linear recombination 172 
templates from three constituent parts: approximately 350 bp PCR fragments of 173 
the FWPV genome from either side, (i) and (ii), of the center of the target gene, 174 
disrupted in the middle by (iii) a VACV p7.5 promoter upstream of the gpt gene. 175 
For each gene, fragment (i) was amplified by primers 1 and 2, fragment (ii) by 176 
primers 5 and 6 and fragment (iii) by primers 3 and 4. Primers 2 and 3, as well as 177 
4 and 5, had 20 bases of complementary sequence, half from the target gene 178 
sequence and half from the p7.5 gpt cassette. Details of primers used for 179 
generation of the library (data not shown) are available upon request. Following 180 
the first round of PCR, products were purified using a Qiaquick PCR purification 181 
kit (Qiagen) and combined into a PCR-OE reaction in order to amplify a product 182 
consisting of the complete gene of interest with gpt inserted into the centre of 183 
the gene. The resulting PCR product was then transfected into FWPV FP9-184 
infected CEF and recombinant viruses were selected for the gpt gene with fresh 185 
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media containing mycophenolic acid (25µg ml-1), xanthine (250µg ml-1) and 186 
hypoxanthine (15µg ml-1) (MXH). Recovered viruses were bulk passaged three 187 
times in CEF in MXH then plaque purified thrice. Viral genomic DNA was then 188 
extracted and analysed by PCR to confirm disruption of the target gene and loss 189 
of parental virus.  190 
 191 
Construction of deletion knock-out mutant FWPV. 192 
An fpv012 deletion mutant, FP9∆012TD (trans dominant), was generated 193 
independently of the FWPV FP9 knockout mutant library by the transient 194 
dominant selection (TDS) method of Falkner (35) , as described previously (36). 195 
Briefly, two 0.6kbp regions of the FP9 genome, comprising (i) 500bp upstream of 196 
fpv012 plus 100bp from the 5’ end of the ORF and (ii) 100bp from the 3’ end of 197 
fpv012 plus 500bp downstream, were amplified by PCR using oligonucleotides 198 
5’-ATCGGGATCCCTTTAGTATTAGTTATTAAACCCGG and 5’-199 
CATTCTGTATTTAACGATGGAATCTACGTTCGGTGTATTAGGATTTACACC for 200 
amplicon (i) and 5’-201 
CCTAATACACCGAACGTAGATTCCATCGTTAAATACAGAATGGTGTTTACTTCC and  202 
5’-ATCGGACGTCCTTAGCAGTGCAGAAGAATTTATC for amplicon (ii). The two 203 
amplicons were joined by PCR-OE (deleting about 800 bp from the fpv012 ORF), 204 
digested with BamHI and AatII then ligated into pGNR (36) to give pGNRdel012. 205 
CEF were infected with FP9 (MOI 0.1 ) and then transfected with pGNRdel012 206 
using Lipofectin (Life Technologies), according to the manufacturer’s 207 
instructions. Twenty-four hours following transfection the media was replaced 208 
with fresh media containing MXH then infection was allowed to proceed for a 209 
further 72 hours. Progeny virus was harvested and plaque purified thrice on 210 
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CEFs in the presence of MXH and then resolution was accomplished by plaque 211 
purification in the absence of MXH. The resolved viruses were tested for loss of 212 
resistance to mycophenolic acid and the genotype of these gpt- viruses were 213 
established by PCR (using internal and flanking primers) following DNA isolation 214 
from infected cells using Wizard SV genomic DNA purification (Promega). In this 215 
way, FP9∆012TD was isolated. 216 
 217 
Construction of knock-in mutant and revertant FWPV. 218 
To construct knock-in viruses expressing TAP-tagged fpv012, transient dominant 219 
(TD) plasmid pUC13-FL012TAP was constructed in two steps. Firstly, the 400bp 220 
3' flanking sequence from fpv012 was amplified by PCR and cloned into the 221 
poxvirus transient dominant TAP vector pUC13TAP (from Prof. G. Smith), such 222 
that the 3' flanking sequence was downstream of the TAP tag, generating the 223 
intermediate plasmid pUC13TAP012-3’. Subsequently the open reading frame 224 
(ORF), minus the stop codon, and 400 bp of upstream sequence was amplified by 225 
PCR and cloned into pUC13TAP012-3’ so that the virus ORF was fused in-frame 226 
with the TAP tag. Constructs were sequenced to ensure no errors had been 227 
introduced. Recombinant TAP-tagged fpv012 virus was generated by transfection 228 
of the construct into CEFs infected with FP9∆012TD. The knock-in mutants were 229 
then isolated by the TDS method, as described above.  230 
 231 
The TDS method described above was also used to construct a revertant virus 232 
from mutant FP9∆012TD. The fpv012 ORF was amplified, with 500 bp flanking 233 
regions, using primers 5’-ATCGGGATCCCTTTAGTATTAGTTATTAAACCCGG and  234 
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5’-ATCGGACGTCCTTAGCAGTGCAGAAGAATTTATC, digested with BamHI and 235 
AatII then ligated into pGNR to generate pGNR012REV. This was used to 236 
generate revertant virus, 012REV, with a reconstituted fpv012 locus by the TDS 237 
method described above. 238 
 239 
RNA extraction and processing of samples 240 
RNA was extracted from cells using an RNeasy kit (Qiagen) according to the 241 
manufacturer’s instructions. On-column DNA digestion was performed using 242 
RNase-free DNase (Qiagen) to remove contaminating genomic DNA. RNA 243 
samples were quantified using a Nanodrop Spectrophotometer (Thermo 244 
Scientific) and checked for quality using a 2100 Bioanalyzer (Agilent 245 
Technologies). All RNA samples had an RNA integrity number (RIN) ≥ 9.6.  246 
 247 
Reverse transcription (RT) PCR and quantitative real-time RT PCR 248 
qRT-PCR was performed using MESA GREEN qPCR MasterMix Plus for SYBR® 249 
Assay I dTTP (Eurogentec) according to the manufacturer’s instructions. A final 250 
volume of 10μl per reaction was used, with 1μl cDNA diluted 1:10 in nuclease-251 
free H2O as a template. Primers (Table 2) were used at a final concentration of 252 
300nM. qPCR was performed on an ABI-7900HT Fast Real-Time PCR System 253 
(Applied Biosystems) using the following programme: 95°C for 5 minutes; 40 254 
cycles of 95°C for 15 seconds, 57°C for 20 seconds, 72°C for 20 seconds; 95°C for 255 
15 seconds; and 60°C for 15 seconds.  256 
The qRT-PCR primer pairs (Table 2) were validated by generating standard 257 
curves using PCR products corresponding to each gene. A 10-fold dilution series 258 
was made for each PCR product and 1 µl was used with the MESA green qPCR 259 
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mastermix. Ct values were analysed using SDS2.3 (Applied Biosystems). The 260 
slopes of the standard curves were used to identify the amplification efficiencies 261 
(E) of the qRT-PCR primer pairs, using the equation E = 10(-1/slope) -1. Only 262 
qRT-PCR primer pairs with efficiencies of 90-110% were used further. The linear 263 
correlation coefficient (R2) was used to assess the linearity of the standard 264 
curve. Standard curves with an R2 value of >0.985 were used. 265 
 266 
Data were analysed using SDS 2.3 and RQ Manager 1.2 software (Applied 267 
Biosystems). All target gene expression levels were calculated relative to 268 
expression levels of the reference gene, glyceraldehyde 3-phosphate 269 
dehydrogenase (GAPDH), which were shown to remain constant over 24 h in 270 
uninfected and FP9-infected cells, and the target gene expression level in control 271 
CEF, using the comparative CT method (also referred to as the 2–ΔΔCT method). 272 
 273 
RESULTS 274 
 275 
Fowlpox virus fails to induce ChIFN2 in chicken DF-1 cells. 276 
Infection of immortalized chicken fibroblast DF-1 cells with FWPV FP9 led to no 277 
detectable induction in the expression of ChIFN2 mRNA, as determined by RNase 278 
protection assay. In contrast, infection with the chicken birnavirus, infectious 279 
bursal disease virus (IBDV) attenuated vaccine strain PBG98 (29) showed clear 280 
induction of ChIFN2 (Figure 1A). 281 
 282 
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To test whether the failure of FWPV to induce ChIFN2 was reflected by a failure 283 
to activate the ChIFN2 promoter, the effects of infection on expression of a 284 
luciferase reporter gene under the control of the ChIFN2 promoter (30), 285 
transfected into chicken DF-1 cells, was examined. Compared to poly(I:C) 286 
transfection or IBDV infection, FWPV infection did not induce the ChIFN2 287 
promoter (Figure 1B and 1D). This effect was seen whether the highly passaged 288 
and attenuated FP9 strain of FWPV or its pathogenic precursor strain (HP1) 289 
were used (Fig. 1B), despite the fact that the former has undergone numerous 290 
mutations including the loss of 22 kbp of genomic sequence (28). 291 
 292 
FWPV actively blocks dsRNA induction of the ChIFN2 promoter. 293 
We next examined whether the failure of FWPV to activate the ChIFN2 promoter 294 
represented a failure to generate a PAMP or the production of an FWPV-encoded 295 
inhibitor of IFN induction. Fig. 1C and 1D show that FWPV-infected DF-1 cells 296 
exhibited a block to subsequent induction of the ChIFN2 promoter by transfected 297 
poly(I:C). In contrast, not only did the positive control IBDV PBG98 fail to block 298 
poly(I:C)-mediated induction of the promoter, it actually enhanced the induction. 299 
The FWPV-mediated block to induction of the ChIFN2 promoter upon virus 300 
infection alone or after subsequent poly(I:C) transfection was confirmed by qRT-301 
PCR in parallel with luciferase reporter assays (Fig. 1 D and E). Infection of 302 
appropriate samples with FWPV was demonstrated by qRT-PCR for FWPV early 303 
and late genes (Fig. 1F). These data indicated that FWPV encodes an inhibitor of 304 
transfected poly(I:C)-mediated ChIFN2 induction.  305 
 306 
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Identification of a knockout mutant of FWPV partially defective in the 307 
ability to block induction of ChIFN2.  308 
A loss-of-function approach was adopted to identify a FWPV gene(s) that blocked 309 
the induction of ChIFN2 by poly(I:C). To facilitate this, a panel of FWPV non-310 
essential gene gpt-insertion knockout mutants (48 single genes and one double 311 
gene; see Table 3), was screened by luciferase reporter assay for complete or 312 
partial loss of the ability of FP9 to block induction of ChIFN2 by transfected 313 
poly(I:C). 314 
 315 
One gpt-insertion knockout mutant consistently demonstrated higher levels of 316 
transfected poly(I:C)-induced luciferase activity compared to parental FP9 and to 317 
the other mutants (see Fig. 2a). This mutant, FP9_012::gpt, had a copy of the gpt 318 
gene inserted in the centre of fpv012. An independent deletion mutant, 319 
FP9∆012TD, generated using the transient dominant method (35, 36) displayed 320 
the same phenotype (Fig. 2b). Multi-step growth curves of the replication of 321 
parental FWPV FP9 and FP9∆012TD in CEF, infected at a multiplicity of infection 322 
(MOI) of 0.01, showed no significantly adverse affect of the fpv012 disruption on 323 
the production of intra- and extra-cellular virus up to 72 h.p.i. (Fig. 3). 324 
 325 
Expression kinetics of fpv012. 326 
Analysis of the kinetics of expression of fpv012 by qRT-PCR revealed that it was 327 
expressed early during FWPV infection, but only weakly so (Fig. 4A). Levels of 328 
fpv012 RNA, relative to GAPDH, were below those observed for control genes 329 
fpv094 (an ortholog of VACV E9L encoding DNA polymerase) and fpv100 (an 330 
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ortholog of VACV E4L encoding RNA polymerase subunit RPO30). Both of the 331 
VACV orthologs showed early expression kinetics (37).  332 
 333 
As expected, no fpv012 expression was detected in cells infected with the fpv012 334 
deletion mutant FP9∆012TD (Fig. 4B) but it was evident in cells infected with the 335 
revertant (Fig. 4C). Analysis of the same data plotted on a linear scale (data not 336 
shown) revealed that in cells infected with the mutant, there appeared to be a 337 
slight delay (1.5 to 2.5 h), relative to those infected with parental or revertant  338 
viruses, in the kinetics of expression of FWPV genes that in this assay appear to 339 
be expressed late (fpv165, fpv168 and fpv176), with half maximal expression at 340 
12 rather than 10 hpi. Expression of the early genes (fpv094 and fpv100) 341 
appeared to be delayed by 3 to 4 h in FP9∆012TD (with half maximal expression 342 
at 7 rather than 3 to 4 hpi). 343 
 344 
Antibodies for fpv012 are unavailable but a recombinant ‘knock-in’ virus, with a 345 
TAP-tagged version of fpv012 inserted into the native locus under control of the 346 
resident promoter, was constructed, allowing demonstration of the expression of 347 
the tagged protein by western blotting of lysates with anti-FLAG antibodies (Fig. 348 
4D). 349 
 350 
Expression of ISGs is elevated in CEF infected with the fpv012 deletion 351 
mutant.  352 
Complex viruses often encode multiple antagonists of IFN-mediated responses, 353 
targeting IFN induction, signalling and antiviral activities of IFN-stimulated 354 
genes (ISG). Releasing the viral block to induction of ChIFN2 might not, 355 
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therefore, lead to expression of ISG if robust blocks to IFN signaling remain 356 
intact. To investigate whether this might be the case for FWPV, CEF were 357 
infected with parental FP9 or the fpv012 deletion mutant and the induction, by 358 
virus infection alone, of selected ISGs was analysed by qRT-PCR (Table 2). 359 
Significant, moderate-level induction of Mx1 by infection with the fpv012 360 
deletion mutant alone, and lower (but highly significant) level induction of 361 
ZC3HAV1, was observed (Fig. 5A) but no significant induction of mda-5/IFIH1 of 362 
ChIFN2 was observed. No significant induction, by virus infection alone, of any of 363 
the ISGs or ChIFN2 was observed for parental FP9. Expression of Mx1, but not 364 
ZC3HAV1, induced by the mutant alone appeared highest at 8hpi. The 365 
experiment (Fig. 5B) was therefore repeated to include an earlier time point 366 
(4hpi), additional ISGs (IFIT5 and ISG12-2) and the revertant virus. This 367 
confirmed that the fpv012 deletion mutant is phenotypically distinct from 368 
parental FP9 and the revertant in terms of ISG expression following virus 369 
infection alone (Fig. 5B). It is clear that Mx1 shows a biphasic response with an 370 
immediate peak of expression at 4hpi, a trough at 8 to 16hpi then increased 371 
expression at 24hpi. A similar profile is shared by IFIT5, though it showed much 372 
higher induction at 24hpi. Another ISG (ISG12-2) showed a different profile, with 373 
no immediate peak at 4hpi but increased expression at 16 and especially 24hpi. 374 
This profile actually resembles that for ChIFN2, which showed trace induction (2 375 
fold) at 24hpi. 376 
 377 
Ectopic expression of fpv012 blocks induction of ChIFN2 378 
Ectopic expression of native or N-terminally FLAG-tagged fpv012, but not of 379 
control fpv155 (N1R/p28-like) nor fpv213, following transfection of the 380 
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pEFPlink2-derived expression plasmid, blocked poly(I:C)-mediated induction of 381 
the ChIFN2 promoter in DF-1 cells when expressed in the absence of other FWPV 382 
proteins (Fig. 6B), offering the opportunity for ready analysis of its activity. 383 
 384 
IFN modulator fpv012 is a member of the ANK/PRANC poxvirus gene 385 
family.  386 
The IFN modulator identified by this study, fpv012, is encoded by a member of 387 
the largest gene family in poxviruses (Fig. 6A), representing those proteins 388 
containing multiple copies of the ankyrin repeat (ANK; INTERPRO IPR002110). 389 
The majority of poxviral ANK proteins, including fpv012, appear to be of a 390 
particular type, ANK/PRANC, with an N-terminal domain (INTERPRO 391 
IPR020683) containing multiple ANKs (4 in the case of fpv012) and a C-terminal 392 
F-box like motif in what has been described by Mercer and colleagues (38) as a 393 
PRANC domain (Pox protein Repeats of ANkyrin – C terminal; INTERPRO 394 
IPR018272). Deletion analysis was therefore used to define whether both of 395 
these domains were required for activity. 396 
 397 
Inhibition of the ChIFN2 promoter is not dependent on fpv012 ankyrin 398 
repeat 1.  399 
In an attempt to analyze the relative importance of the ANK domain and the C-400 
terminal F-box like motif in the ability of fpv012 to inhibit the induction of 401 
ChIFN2 by poly(I:C), a panel of fpv012 variants with domain deletions (Fig. 6B) 402 
was generated and examined in transient transfections.  Unfortunately, the levels 403 
of expression of wild-type and mutant fpv012 from the constructs were too low 404 
to allow investigation of expression and/or stability of the mutated proteins by 405 
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western blot analysis using anti-FLAG antibody. Nevertheless, the first ANK 406 
appears to be dispensable for the inhibitory activity of fpv012, with Mut1 407 
displaying as much inhibitory activity as full-length or N-terminally Flag-tagged 408 
fpv012 (Fig. 6B). Removal of additional ANKs from the N-terminus (in Mut2 and 409 
Mut3) or deletion of just 13 amino acids from the C-terminus (Mut4), 410 
downstream of the acknowledged F-box motif (38), completely abrogated the 411 
inhibitory effect (Fig. 6B) but we cannot eliminate the possibility that the loss of 412 
inhibitory activity is due to reduced stability of the truncated proteins. 413 
 414 
cnpv030, the canarypox virus ortholog of fpv012, also inhibits poly(I:C) 415 
induction of the ChIFN2 promoter.  416 
Although both CNPV and FWPV are members of the Avipoxvirus genus, they are 417 
considerably diverged, they are found in different major clades of the genus (39) 418 
and they display significant differences in gene complement (20, 40). 419 
Comparisons between ANK proteins can be problematic but extensive 420 
phylogenetic analysis (41) revealed that fpv012 is most similar (45% amino acid 421 
identity) to an ANK protein, cnpv030, from CNPV. Genes fpv012 and cnpv030 422 
appear to be in relatively syntenic, yet diverged, locations within their respective 423 
genomes (Fig. 7), in that cnpv030 is flanked by orthologs of fpv011 (cnpv025) and 424 
fpv016 (cnpv032). Moreover, ectopic expression of cnpv030 appeared to be as 425 
effective as fpv012 at blocking the transfected poly(I:C)-mediated induction of 426 
the ChIFN2 promoter (Fig. 6B), indicating that the possession of genes for 427 
modulating the induction of the avian equivalent of IFN-β is probably conserved 428 
across the avipoxvirus genus. 429 
 430 
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DISCUSSION 431 
 432 
Although poxviruses have dsDNA genomes, they have long been known to 433 
produce dsRNA by production of convergent, heterogeneous length, 434 
complimentary late transcripts (42). Indeed a VACV mutant temperature 435 
sensitive in transcription factor A18 produces more dsRNA, which leads to 436 
increased activation of 2’, 5’-oligoadenylate synthetase (OAS) (43). VACV E3 has 437 
long been known to play a major role in resisting the antiviral effects of IFN, 438 
sequestering dsRNA and thereby preventing allosteric activation of the dsRNA-439 
dependent protein kinase, PKR, and OAS (44). More recently, E3 was also shown 440 
to inhibit activation of IRF3 (45), mediated via PKR and IPS-1 (46), thereby 441 
interfering with induction of IFN-β. Although avipoxviruses lack an ortholog of 442 
E3, parental FP9 is able to block transfected poly(I:C)-mediated induction of 443 
ChIFN2 (Fig. 1) so we sought to identify proteins involved. 444 
 445 
The genetic strategy employed identified fpv012*, a member of a large 446 
avipoxvirus gene family encoding ANK proteins, most of which have C-terminal 447 
F-box motifs in so called PRANC domains. Extensive passage (more than 430 448 
times) of pathogenic FWPV HP1 through CEF culture by Anton Mayr, with 449 
concomitant attenuation (47), led to the loss or disruption in FP9 of 12 of the 31 450 
FWPV ANK genes, but fpv012 was not affected (28).  451 
 452 
                                                        
* FWPV gene names are italicized, the equivalent protein names are not. 
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Many studies with mammalian poxviruses have demonstrated the role of 453 
multiple viral modulators in controlling host IFN responses at various levels. 454 
Data shown in Fig. 2 indicate that fpv012 is responsible for blocking about 20% 455 
of expression from the ChIFN2 promoter induced by transfected poly(I:C), 456 
suggesting that the deletion mutant still has another mechanism(s) to control 457 
induction of ChIFN2. The additional mechanisms for controlling ChIFN2 458 
induction appear to be sufficient, even in the absence of fpv012, to control the 459 
bulk of the residual ChIFN2 induction stimulated by virus infection as infection 460 
alone by the fpv012 deletion mutant virus stimulated only trace increase (not 461 
more than 2 fold at 24hpi) induction of ChIFN2 over that observed for FP9 462 
infection alone (Fig. 5). Nevertheless, infection alone with the fpv012 deletion 463 
mutant, but not with FP9, led to significant, moderate-level induction of the ISGs 464 
Mx1, ISG12-2 and especially IFIT5 and lower level (but highly significant) 465 
induction of ZC3HAV1 (Fig. 5A and B). Several studies have described induction 466 
of such IFN-induced downstream effectors by avian viruses in avian systems (48, 467 
49). Increased expression of the effectors in cells infected by the fpv012 deletion 468 
virus might be attributable to the induced trace level expression of ChIFN2. We 469 
cannot exclude the possible involvement of alternative, IFN-independent 470 
pathways in induction of the ISG, especially given the different kinetic expression 471 
profiles observed for the various ISGs, although it should be stressed that any 472 
such pathways are also clearly normally blocked by fpv012. Clarifying this issue 473 
will need extensive study of the chicken innate responses, which remain 474 
relatively poorly characterized, but fpv012 should prove a useful tool in those 475 
studies. 476 
 477 
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Despite moderate level induction of ISGs, and some delay in expression of viral 478 
genes, the fpv012 deletion virus did not appear to be significantly compromised 479 
in its replicative capacity in tissue culture (Fig. 3). This indicates that virus 480 
mechanisms for subverting the antiviral effectors must exist in FWPV and must 481 
remain intact in the fpv012 deletion mutant. We have identified fpv014 as a 482 
contributor to chicken type I IFN resistance in VACV MVA/FWPV chimaeras (see 483 
accompanying manuscript by Buttigieg et al.; JVI02738-12) but, based on the 484 
VACV paradigm, it is likely that more genes will be involved. 485 
 486 
Ectopic expression of fpv012 leads to inhibition of transfected poly(I:C)-mediated 487 
induction of the ChIFN2 promoter (Fig. 6). This phenotype offered the ready 488 
opportunity to analyse the viral determinants of modulation. Unfortunately, the 489 
levels of expression of wild-type and mutant fpv012 from the constructs were too 490 
low to allow investigation of expression and/or stability of the mutated proteins 491 
by western blot analysis using anti-FLAG antibody. Nevertheless, the data shown 492 
in Fig. 6 demonstrate that the first ANK is dispensable for the inhibitory activity 493 
of fpv012. Although removal of further ANKs or just 12 residues from the C-494 
terminus of fpv012 disrupted its function when expressed ectopically (Fig. 6B), 495 
we were not able to confirm stability of the truncated protein so detailed 496 
mutagenic analysis of fpv012 must await an extensive study using expression of 497 
mutated FLAG-tagged proteins expressed from knock-in virus mutants .  498 
In an accompanying manuscript (Buttigieg et al.; JVI02378-12), we demonstrated 499 
interaction between the fpv014 ANK/PRANC protein involved in ChIFN1 500 
(chicken IFN-α) resistance and proteins of the SCF (Skp-1, Cullin-1, F-box) 501 
ubiquitin ligase complex, as has been observed for a number of mammalian 502 
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poxvirus ANK proteins (50-54). It is postulated (38) that such interactions allow 503 
ANK/PRANC proteins to act as adapters, targeting for ubiquitination (and 504 
probable proteasomal degradation) ligands captured by the N-terminal ANK 505 
domains.  Despite considerable effort, probably because of the low levels of 506 
expression of fpv012 in the various systems, we have so far been unable to 507 
identify interaction of fpv012 with the SCF complex.  We have also been unable 508 
to identify any cellular proteins captured by the N-terminal ANK domain of 509 
fpv012, but ligands for this family of proteins have proved generally elusive. 510 
Thus far, the only ligands identified are Akt, for myxoma virus MT-5 (55), and 511 
NF-κB, for variola virus G1 (56) and its cowpox virus (CPXV) ortholog CPXV006 512 
(57), as well as for CPXV CP77, encoded by CPXV025 (51). 513 
 514 
It is not clear why so many ANK proteins are encoded by the avipoxviruses. The 515 
difference in numbers of ANK protein genes carried by relatively closely related 516 
viruses (e.g. 31 in FWPV and 51 in CNPV) suggests that gene expansion involves 517 
duplication and subsequent evolution. Such expansion, driven by IFN, has 518 
recently been demonstrated (using deep sequencing) for VACV in cell culture 519 
(58). In a genetic background defective for E3L, the copy number of the K3L gene 520 
was observed to expand allowing it to mutate and evolve so that it was more 521 
effective at inhibiting PKR. The authors coined the term “viral gene-accordions” 522 
for this mechanism, as selection of an advantageous allele allowed subsequent 523 
contraction in copy number (58). They also recognised that the expansion of the 524 
ANK genes in avipoxviruses is a “particularly clear example of such adaptive 525 
gene expansions” and, moreover, that it represents “an exceptional example” 526 
whereby multiple functional variants have been generated so that the accordion 527 
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has not collapsed to a single copy. Our demonstration that fpv012 and cnpv030, 528 
which are an orthologous pair (41), share the ability to block induction of avian 529 
IFN-β provides a strong indication that ANK gene expansion in the avipoxviruses 530 
pre-dates speciation of FWPV & CNPV, particularly as fpv012 and cnpv030 are far 531 
from basal to the avipoxvirus ANK phylogenetic tree (see supplemental figure of 532 
Sonnberg et al. (41)). 533 
 534 
Expansion of such a large complement of related genes to the extent seen for this 535 
“viral gene accordion” might initially have facilitated high-level expression of 536 
inhibitors of a limited number of targets by a gene dosage effect (58). 537 
Subsequent selection and evolution might have allowed the targeting of a limited 538 
number of host factors in a redundant manner, as seen for binding of NF-κB by 539 
both CPXV006 and CPXV025 (51, 57). Ultimately, the accordion might have 540 
become capable of targeting multiple, distinct, cellular proteins. Our 541 
demonstration of different functions for two avipoxvirus ANK proteins (fpv012 542 
here and fpv014 in the accompanying manuscript Buttigieg et al.; JVI02378-12), 543 
both of which fall in the same larger phylogenetic cluster of avipoxvirus ANK 544 
genes  (see supplemental figure of Sonnberg et al. (41)), hints at a complex and 545 
highly dynamic evolutionary picture. There is clearly wide scope for evolutionary 546 
selection of functions for the avipoxvirus ANK genes - it is notable that 547 
avipoxviruses lack equivalents of mammalian poxvirus genes encoding a family 548 
of related proteins with structural homology to cellular Bcl-2 (note that fpv039, 549 
an antiapoptotic, Bcl-2-like FWPV protein (59), appears to be unrelated (60)). In 550 
VACV, these proteins (A46, A52, B14, C1, C6, C16/B22, K7 and N1 (60-66)) target 551 
host factors involved in immunomodulation and the control of apoptosis. It is 552 
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likely that these genes represent another “viral gene-accordion”.  It will be 553 
interesting to discover whether the avipoxvirus ANK protein family has evolved 554 
to recognize a range of targets similar to that of the VACV Bcl-2-like proteins. 555 
 556 
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FIGURE LEGENDS 813 
 814 
Figure 1. Induction of the ChIFN2 promoter upon transfection with 815 
poly(I:C) and/or infection with viruses. (A) RNase protection analysis of 816 
expression of ChIFN2 in DF-1 cells upon virus infection. DF-1 cells, mock treated 817 
or infected with virus (FWPV FP9 or IBDV strain PBG98) for the times stated, 818 
were analysed for expression of ChIFN2 by RNase protection using 10 μg RNA. 819 
The levels of control Chβ-actin are also shown. (B to D) Luciferase reporter 820 
analysis of expression of ChIFN2 in DF-1 cells. DF-1 cells were transfected with 821 
the ChIFN2 promoter luciferase reporter plasmid (pChIFN2lucter) and plasmid 822 
pJATlacZ, constitutively expressing β-galactosidase from the rat β-actin 823 
promoter (31). Following recovery for 24 hours cells were either left uninfected 824 
or infected (at an MOI of 10) with poxviruses (attenuated FWPV FP9 or its 825 
progenitor HP1) or attenuated IBDV vaccine strain PBG98. Following infection 826 
for four hours, cells were either left untreated or transfected with poly(I:C) 827 
(10µg ml-1) and incubated for 16 hours. Luciferase expression values were 828 
normalised to those of β-galactosidase. ChIFN2 expression levels were compared 829 
to the uninduced control to calculate the fold induction. (B) Induction of the 830 
ChIFN2 promoter by transfected poly(I:C), as a positive control, or by infection 831 
alone. (C) Modulation of induction of the ChIFN2 promoter, mediated by 832 
transfected poly(I:C), following infection with FWPV (FP9 or HP1) or IBDV 833 
PBG98. (D and E) Modulation of induction of the ChIFN2 promoter, mediated by 834 
virus infection or by transfected poly(I:C), following infection with FWPV FP9 or 835 
IBDV PBG98. Samples from the same experiment were split for luciferase assay 836 
(D) and for qRT-PCR (E). ChIFN2 expression levels were calculated relative to 837 
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GAPDH and the untreated control. (F) The same samples as in (D) and (E) were 838 
tested for expression of early (fpv094) and late (fpv176) genes by qRT-PCR. 839 
Their expression was normalized against GAPDH and is presented relative to 840 
that in the FP9 sample. 841 
 842 
Figure 2. Screening FWPV FP9 mutants for reduced ability to block 843 
poly(I:C)-mediated induction of the ChIFN2 promoter. (A) Chicken DF1 cells 844 
were transfected with the ChIFN2 promoter reporter (pChIFN2lucter) and the 845 
constitutive LacZ reporter plasmid pJATlacZ. Following recovery for 24 hours, 846 
cells were either left uninfected or infected with parental FWPV FP9 or single-847 
gene mutants of FP9, at an MOI of 10. Following infection for 4 hours, cells were 848 
either left untreated or were transfected with poly(I:C) (10µg ml-1) and 849 
incubated for 16 hours. Luciferase assays were carried out and data were 850 
normalised using β-galactosidase measurements. Each sample was compared to 851 
the uninfected, poly(I:C)-treated control to calculate percent induction. Results 852 
show the mean (n=3) + SD. (A) The results of an experiment screening 15 single-853 
gene insertion mutants. (B) Blocking of induction of the ChIFN2 promoter by two 854 
independently isolated fpv012 mutants, created by two different methods (gpt 855 
selection cassette insertion, FP9_012::gpt, or trans-dominant selection-mediated 856 
deletion, FP9∆012TD), is compared with that observed for parental FP9.  857 
  858 
Figure 3.  Multi-step growth kinetics of parental FWPV FP9 and transient 859 
dominant selection deletion mutant FP9∆012TD.  Chick embryo fibroblasts 860 
(CEF) were infected with FP9 or FP9∆012TD at an MOI of 0.01. Extracellular 861 
(supernatant) and intracellular (cells) samples were harvested at 2, 10, 24, 48 862 
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and 72 hours post infection. Samples were freeze thawed three times and virus 863 
titre determined in triplicate using plaque assay. 864 
  865 
Figure 4. qRT-PCR analysis of FWPV gene expression by parental, 012 866 
mutant and revertant viruses. Expression of mRNA specific for fpv012 was 867 
assayed by qRT-PCR, using as controls FWPV genes: fpv094 (ortholog of VACV 868 
E9L; DNA polymerase), fpv100 (ortholog of VACV E4L; RNA polymerase subunit 869 
RPO30), fpv165 (ortholog of VACV A2L; VLTF-3 late transcription factor), fpv168 870 
(39K core protein (67, 68); ortholog of VACV A4L) and fpv176 (ortholog of VACV 871 
A12L). Expression was standardized against that for ChGAPDH. Graphs show the 872 
results for parental FP9 (A), FP9∆012TD (B) and revertant  (C) viruses from two 873 
experiments (mean +/- SD). (D) Expression of TAP-tagged fpv012 (with TAP-874 
tagged fpv014 as a control) inserted back into the native locus in FWPV FP9 875 
under control of its cognate promoter, in infected CEF and DF-1 cells. TAP-tagged 876 
proteins were detected by immunoblotting of SDS polyacrylamide gels with anti-877 
FLAG antibody (Sigma) and anti-mouse secondary antibody (LI-COR) as per the 878 
manufacturers’ protocols. The immunoblots were imaged using a LI-COR 879 
Odyssey infrared imaging system. Samples were obtained at 24 hpi (MOI=3). 880 
Molecular weight markers (M) are shown, as are the predicted masses of TAP-881 
tagged fpv012 (41 kDa) and TAP-tagged fpv014 (53 kDa). 882 
 883 
Figure 5. qRT-PCR analysis of IFNb and ISG mRNA expression after infection 884 
with parental, fpv012 deletion mutant or revertant FP9. CEF were infected  885 
(MOI = 5) with parental FP9, Δ012TD or 012REV (B only) and harvested for RNA 886 
extraction at 0, 4 (B only), 8, 16 and 24 h post infection. Total RNA was extracted 887 
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from samples, cDNA was synthesised and qRT-PCR was performed in triplicate 888 
to quantify relative expression kinetics. Panels (A) and (B) show the results from 889 
2 different experiments, using completely different batches of CEF. Bar graphs 890 
show the results from three experiments (mean +/- SD), each performed with a 891 
different batch of CEF. Asterisks indicate probability (2-way ANOVA followed by 892 
Bonferroni post-hoc test: * P < 0.05, ** P < 0.01, *** P < 0.0001). Data were 893 
normalized against ChGAPDH and are presented relative to mock infected (A) or 894 
parental FP9-infected (B). 895 
 896 
Figure 6. Domain structure and deletion mutant analysis of fpv012.  897 
(A) Domain structure of fpv012 showing N-terminal ankyrin (ANK) repeats as 898 
well as the C-terminal F-box motif and the larger, encompassing PRANC domain. 899 
To scale. (B) Schematic illustrating the position of deletions of fpv012 in 900 
pEF012Flag mutants 1 to 4 (Mut1(∆aa1-42), Mut2(∆aa1-74), Mut3(∆aa1-108), 901 
Mut4 (∆aa319-331) with comparison of the ability of the FLAG-tagged parental 902 
(pEF012Flag) and mutant forms (pEF012FlagMut1 to 4) of fpv012 to block 903 
poly(I:C)-mediated induction of the ChIFN2 promoter. Empty pEFPlink2 vector, 904 
vector expressing native or FLAG-tagged fpv012 (pEF012 and pEF012FLAG, 905 
respectively) or vectors expressing other FWPV genes (fpv155 or fpv213; 906 
pEF155, pEF213, respectively) served as controls. The ability of the CNPV 907 
ortholog of fpv012, (CNPV030) expressed from pEFPlink2 (pEFCNPV030), to 908 
block the ChIFN2 promoter was also assayed. 909 
 910 
Figure 7. Comparative genomic organization of the fpv010 to fpv016 locus 911 
in FWPV and CNPV. Genes conserved between FWPV and CNPV are shown as 912 
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filled boxes; non-conserved genes are shown as open blocks. The arrowhead at 913 
the end of each block shows the direction of transcription. Reading frames (RF) 914 
are indicated. Short and long dashed lines correlate the left and right ends of the 915 
genes, respectively, in the two avipoxviral genomes. To scale.  916 
917 
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TABLES 918 
 919 
Table 1. Primers used for constructing expression clones. 920 
Gene Vector Fwd/Rev Primer sequence 5’-3’
CNPV030 pEFPlink2 Fwd CCGGATCCTCAGTCACGATGGATTTACC 
CNPV030 pEFPlink2 Rev CGATACTAGTTTATTTGTGTATATTTAAAGCG 
FPV012 pEFPlink2 Fwd CCGGATCCATGGATACAGAAATGGACGG 
FPV012 pEFPlink2 Rev GGTTCCACTAGTTTAACCAGTCTTATTATTAAC 
FPV012 pEFPlink2Flag Fwd CCGGATCCGATACAGAAATGGACGGTGTCAATAACG 
FPV012MUT1-126(Mut1) pEFPlink2Flag Fwd CCGGATCCGTAGATTCCTACACTCCGTTAC 
FPV012MUT1-222(Mut2) pEFPlink2Flag Fwd CCGGATCCACTAATGATGGTTATACGGCTC 
FPV012MUT1-324(Mut3) pEFPlink2Flag Fwd CCGGATCCAAATACGGTATTACTCCTCTTG 
FPV012 pEFPlink2Flag Rev CGATACTAGTTTAACCAGTCTTATTATTAACTTTAATAGCG 
FPV012MUT955-996(Mut4) pEFPlink2Flag Rev CGATACTAGTTTACAATTTTTTTATATTATCGTTATTAAG 
FPV155 pEFPlink2Flag Fwd CCGGATCCATGTTTAATAGTATGATAACCGG 
FPV155 pEFPlink2Flag Rev CGATACTAGTTTAGTTATCTGAAAATATTTTATTTATATCC
FPV213 pEFPlink2Flag Fwd GCATCCATGGGGGAACGAGTAAAAAAATGTTTTAG 
FPV213 pEFPlink2Flag Rev CGATGGATCCTTAGCTATCCTGTAAAGGAGATAC 
921 
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Table 2. Primers used to quantify gene expression in real-time qRT-PCR  922 
Gene Accession 
number 
Forward PCR primer 5’-3’ Reverse PCR primer 5’-3’ 
ChGAPDH NM_204305.1 GGCACTGTCAAGGCTGAGAA TGCATCTGCCCATTTGATGT 
ChIFN2 GU119897.1 CAAGGCACGCGCTCCCAGAG TGTGCCGTAGGAAGTTGTGGATGG 
ChMX1 HM775376.1 GACCAGTACCGCGGACGGGA CGCAACAGCTGGCTCCTCCA 
ChZC3HAV1 NM_001012938.1 TCGGCGCCTCTCTACGCCAT TCAGTCCACTGGCCGTGGTCA 
ChIFIH1/MDA5 AB371640.1 TTGCTATGGTGCAGGCCCGG TGGCGGCATCTCTTGGACACG 
ChIFIT5 NW_003763812.1 TGACCAGCCAAGGGGATGGCT AGAGGGATTTGGGAGTGCTTCAGC 
ChISG12-2 NM_001001296.4 TGACCAGAACGTCCACAAAGCCG ACCTGCTCCTGGACCGATGCTT 
fpv012 AJ581527 CACCCTCATCTAACAAAACA CGCTAAAACGGGCAATATAA 
fpv094 AJ581527 TATAATGAATGGCGCTGTGT GTTTTGCTATCTTGGCTGT 
fpv100 AJ581527 GTGTTCACGCCAAAGTAG AGTAGGTTCTTCGTCAGATG 
fpv126 AJ581527 AACAACGAACAAATACCC AATCCAAGTAGCATATCAAG 
fpv165 AJ581527 CCCCAAACGGTTAAAAACTACACG ACGTATTCGTGTCCGTAATCGT 
fpv168 AJ581527 ACCTCAAACAACCTCATC GTTAATACTTGTGACTGCTG 
fpv176 AJ581527 ACGTGTCCCTTTACCTCC TTCCTTGCCATCTACGCC 
 923 
924 
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Table 3. FWPV FP9 gene knockouts screened for loss of ability to block 925 
poly(I:C) induction of ChIFN2luc reporter 926 
 927 
Targeted FWPV FP9 gene (Gene prediction and/or VACV ortholog) 
006 (C4/C10L) 080 (TGF-β) 
010 (SERPIN) 092 (E11L) 
011 (SNAP) 097 / 098 (VARV B22R) 
012 (ANK) 099 (VARV B22R) 
014 (ANK) 105 (F15L) 
016 (IFN-γ-binding protein) 107 (VARV B22R) 
017 (V Ig domain) 109 (F12L) 
018 (ANK) 119 (G6R) 
020 (C4/C10L) 122 (VARV B22R) 
021 (GPCR) 150 (N1R/p28) 
022 (ANK) 155 (N1R/p28) 
023 (ANK) 213 (Unknown) 
024 (ANK) 216 (ANK) 
026 (ANK) 217 (NPHV protein) 
027 (GPCR) 219 (ANK) 
034 (ANK) 224 (ANK) 
040 (SERPIN) 226 (B1R; S/T kinase) 
044 (SERPIN) 227 (ANK) 
046 (A44L; steroid DH) 228 (ANK) 
047 (Semaphorin; A39L) 229 (A47L?) 
048 (ELOVL4) 230 (ANK) 
055 (V Ig domain) 231 (ANK) 
063 (Unknown) 232 (ANK) 
075 (N1R/p28) 011 / 033 (SNAP double K/O) 
076 (β-NGF)  
 928 
Gene assignments as described previously (28). ‘K/O’, knockout. 929 
 930 
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